Australia Current Account Deficit Widens to A$27.2 Billion 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
CIA-Linked Investor Helped Quantum Systems Expand in US 
German Retail Sales Drop 3.4% in July 
Bank of England Sees Surge in Higher-Risk Collateral 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Asian Stocks Tumble as Oil Surge Fuels Rate Hike Fears 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Oil Prices Rise as U.S.-Iran Fighting Fuels Supply Fears 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
Genexine, the South Korean biotechnology company, is said to have made a deal with PT Kalbe Farma, an Indonesian pharmaceutical firm. The contract is about the supply of 10 million doses of the COVID-19 vaccine that it is currently developing.
The vaccine supply deal
The information about Genexine’s agreement with the Indonesian pharma was reported on Tuesday, April 27. While the Korean company is not done yet with the clinical tests for its vaccine brand, PT Kalbe Farma is confident enough for its effectiveness since it already placed an order.
But then again, The Korea Herald pointed out that the deal is not fully done yet. This is because the sale will only be possible if the government of Indonesia will approve the Genexine vaccine for emergency use.
Once everything is ironed out, the purchase of 10 million doses of coronavirus vaccine that Genexine named GX-19NA will be finalized. At this point, it was mentioned that the shot is still in the second phase of the clinical trial. A third one is expected to follow soon.
After the purchase, it was reported that Genexine will be receiving royalties based on sales of the vaccine through PT Kalbe Farma.
Phase 3 of the clinical trial
Genexine and PT Kalbe Farma have submitted applications for the second and third stages of the trials to the Indonesian Food and Drug Authority. The latter will be funding the cost of the clinical studies and since this is the arrangement, Genexine will not be given a downpayment for the order of 10 million doses, Korea Bio Med reported.
They also forwarded an application for an investigational new drug (IND) to the Indonesia National Agency of Drug and Food Control. It has been almost a month since the submission and they are waiting for approval.
"Indonesia has faith in the safety and efficacy of GX-19N, promised to conduct the joint clinical trials, and pre-ordered the vaccine candidate," Woo Jung Won, Genexine’s chief executive officer, said. "We will provide a safer Covid-19 vaccine for Indonesia and Korea through the successful development of GX-19N."
Meanwhile, no serious adverse effects were noted in the clinical trials that have been done so far.
